Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Stock Report

Market Cap: US$14.0b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Intra-Cellular Therapies Past Earnings Performance

Past criteria checks 0/6

Intra-Cellular Therapies has been growing earnings at an average annual rate of 10.9%, while the Pharmaceuticals industry saw earnings growing at 8% annually. Revenues have been growing at an average rate of 60.7% per year.

Key information

10.86%

Earnings growth rate

20.06%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate60.75%
Return on equity-6.50%
Net Margin-10.97%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Seeking Alpha • Mar 05

Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition

Summary Intra-Cellular Therapies' Caplyta shows strong sales growth and label expansion potential, making it a valuable acquisition for Johnson & Johnson at $14 billion. JNJ's acquisition of ITCI is strategic, replacing its aging Invega with Caplyta, which has patent protection until 2033 and ongoing clinical trials for new formulations. The $14 billion price tag is justified given Caplyta's advanced clinical stage, FDA approvals, and potential blockbuster status in the schizophrenia and bipolar disorder markets. Schizophrenia and MDD markets are substantial, with Caplyta positioned to capture significant market share, enhancing JNJ's portfolio amidst broader portfolio challenges. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies

Summary Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion or $132 per share. Caplyta's peak sales potential exceeds $5 billion in the hands of J&J, driven by growth in schizophrenia, bipolar disorder, and the pending approval in major depressive disorder. The deal also brings Intra-Cellular Therapies' early-stage pipeline that adds to the long-term upside potential of the deal. Intellectual property risk on Caplyta is substantially reduced with last week's settlement with Sandoz, but not entirely eliminated as it does not stop other generic manufacturers from trying. I believe J&J is paying (at least) a fair price, with decent likelihood of creating substantial long-term value for the company. Read the full article on Seeking Alpha
Seeking Alpha • Dec 09

Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move

Summary CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it as an adjunctive therapy for major depressive disorder, addressing a significant unmet need. Lenrispodun, a PDE inhibitor, is in a phase 2 study for Parkinson's Disease, with potential data release by late 2025/early 2026, offering another blockbuster opportunity. Financially stable with $1 billion in cash and investments, but may raise funds in 2025 to support sales force expansion and R&D programs. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Peaking Back In On Intra-Cellular Therapies

Summary Intra-Cellular Therapies has shown significant progress since we last looked at it in November, with its stock rising nearly 30% since then and CAPLYTA prescriptions growing 36% YoY. CAPLYTA is also poised for FDA approval for major depressive disorder, potentially expanding its market significantly, with an sNDA submission expected in the second half of 2024. The company reported strong Q2 results, with revenues up 45% YoY and a reduced net loss, while analysts remain largely positive with multiple Buy ratings. However, despite positive developments, the stock appears fully valued, trading at over 10 times revenues and 100 times FY2025E EPS, with notable insider selling in August. An updated analysis around Intra-Cellular Therapies follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jun 19

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Summary Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027. I recommend buying ITCI stock as a high-risk, high-return component of a barbell investment strategy. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Summary Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achieved with statistical significance. The Major Depressive Disorder market across the eight major markets is expected to reach $9.6 billion by 2029. Results from the second phase 3 study using lumateperone as an adjunctive therapy for MDD, Study 502, are expected to be released in Q2 of 2024. With two positive phase 3 studies achieved, there is the potential for submission of New Drug Application of lumateperone to the FDA for the treatment of patients with MDD in the 2nd half of 2024. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Intra-Cellular Therapies makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ITCI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24681-755040
30 Sep 24614-864710
30 Jun 24565-844450
31 Mar 24514-1114240
31 Dec 23464-1404100
30 Sep 23420-1554000
30 Jun 23366-1843830
31 Mar 23311-2283820
31 Dec 22250-2563590
30 Sep 22188-2983440
30 Jun 22138-3213260
31 Mar 22103-3042950
31 Dec 2184-2842730
30 Sep 2171-2592510
30 Jun 2156-2372330
31 Mar 2138-2322050
31 Dec 2023-2271860
30 Sep 2010-2071510
30 Jun 203-1871130
31 Mar 201-160870
31 Dec 190-148650
30 Sep 190-148510
30 Jun 190-155440
31 Mar 190-154350
31 Dec 180-155300
30 Sep 180-145270
30 Jun 180-126240
31 Mar 180-106240
31 Dec 170-98240
30 Sep 170-95250
30 Jun 170-102260
31 Mar 170-116260
31 Dec 160-116250
30 Sep 160-118240
30 Jun 160-120220
31 Mar 160-110190
31 Dec 150-105180
30 Sep 150-91150
30 Jun 150-65140
31 Mar 150-48120
31 Dec 141-31100
30 Sep 141-2490
30 Jun 142-2280

Quality Earnings: ITCI is currently unprofitable.

Growing Profit Margin: ITCI is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ITCI is unprofitable, but has reduced losses over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.5%).

Return on Equity

High ROE: ITCI has a negative Return on Equity (-6.5%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/01 15:20
End of Day Share Price 2025/04/01 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intra-Cellular Therapies, Inc. is covered by 6 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert HazlettBTIG
Jason ButlerCitizens JMP Securities, LLC
Corinne JohnsonGoldman Sachs